# AdipoPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adipopharma

- Industry: Biotechnology
- Headquarters: France
- Website: www.adipopharma.com
- Total disclosed funding: $0.3M
- Latest round: Series A (Aug 29, 2023)
- Investors on record: 2

## About

Based in France, and founded in 2007, AdipoPharma SAS operates as a life science company that provides treatments for type 2 diabetes. The company was founded by its president, Vincent Marion. In January 2023, AdipoPharma raised Series A funding led by Newton Biocapital Partners, Good Growth Capital. As of 2023, the company had 10 employees.

AdipoPharma provides and develops drugs for insulin resistance, non-alcoholic fatty liver disease,  and type 2 diabetes. The company’s product line includes a therapeutic peptide called PATAS, which is an anti-diabetic drug that reduces comorbidities such as liver steatosis and fibrosis while enhancing cardiovascular and pancreatic functions.

The company plans to use the funds raised in January 2022 to invest in product development.

## Funding rounds

- Series A, Aug 29, 2023, $0.3M — Good Growth Capital, Newton Biocapital Partners

## Investors

- Good Growth Capital (https://capitalatlas.ai/funds/good-growth-capital) — Series A
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series A